Phase II trial of aflibercept with FOLFIRI as a second‐line treatment for Japanese patients with metastatic colorectal cancer
T Denda, D Sakai, T Hamaguchi, N Sugimoto… - Cancer …, 2019 - Wiley Online Library
Aflibercept targets vascular endothelial growth factor. The present study involved assessing
the efficacy, safety and pharmacokinetics of aflibercept plus 5‐fluorouracil/levofolinate …
the efficacy, safety and pharmacokinetics of aflibercept plus 5‐fluorouracil/levofolinate …
[HTML][HTML] Aflibercept plus FOLFIRI for second-line treatment of metastatic colorectal cancer: observations from the global aflibercept safety and health-related quality-of …
RP Riechelmann, V Srimuninnimit, R Bordonaro… - Clinical colorectal …, 2019 - Elsevier
Background The objectives of this study were to evaluate the safety profile of aflibercept and
health-related quality of life (HRQL) in patients with metastatic colorectal cancer (mCRC) …
health-related quality of life (HRQL) in patients with metastatic colorectal cancer (mCRC) …
Efficacy of aflibercept with FOLFOX and maintenance with fluoropyrimidine as first‑line therapy for metastatic colorectal cancer: GERCOR VELVET phase II study
Aflibercept in combination with 5‑fluorouracil (5‑FU)/irinotecan improves overall survival in
the second‑line therapy of patients with metastatic colorectal cancer (mCRC). In this study …
the second‑line therapy of patients with metastatic colorectal cancer (mCRC). In this study …
[HTML][HTML] Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer …
J Tabernero, E Van Cutsem, R Lakomý… - European journal of …, 2014 - Elsevier
Purpose The antiangiogenic agent aflibercept (ziv-aflibercept in the United States) in
combination with 5-fluorouracil, leucovorin and irinotecan (FOLFIRI) significantly improved …
combination with 5-fluorouracil, leucovorin and irinotecan (FOLFIRI) significantly improved …
Aflibercept: a review in metastatic colorectal cancer
YY Syed, K McKeage - Drugs, 2015 - Springer
Aflibercept is a recombinant fusion protein that acts as a soluble decoy receptor for vascular
endothelial growth factor (VEGF), a key regulator of angiogenesis. It binds to all isoforms of …
endothelial growth factor (VEGF), a key regulator of angiogenesis. It binds to all isoforms of …
Aflibercept plus FOLFIRI in Asian patients with pretreated metastatic colorectal cancer: a randomized phase III study
J Li, R Xu, S Qin, T Liu, H Pan, J Xu, F Bi, R Lim… - Future …, 2018 - Taylor & Francis
Aim: To investigate whether the benefit of combining aflibercept with 5-fluorouracil, folinic
acid and irinotecan (FOLFIRI) chemotherapy could be confirmed in patients from the Asia …
acid and irinotecan (FOLFIRI) chemotherapy could be confirmed in patients from the Asia …
Effectiveness and safety of aflibercept for metastatic colorectal cancer: retrospective review within an early access program in Spain
J Feliu, I Díez de Corcuera, JL Manzano… - Clinical and …, 2017 - Springer
Purpose In the VELOUR study, aflibercept+ FOLFIRI regimen resulted in improved survival
in metastatic colorectal cancer (mCRC) patients who progressed after oxaliplatin. The use of …
in metastatic colorectal cancer (mCRC) patients who progressed after oxaliplatin. The use of …
Aflibercept for metastatic colorectal cancer: safety data from the Spanish named patient program
M Salgado Fernandez, MT Perez Hoyos… - Expert Opinion on …, 2015 - Taylor & Francis
Objective: Aflibercept increased overall survival with acceptable tolerability in metastatic
colorectal cancer (mCRC) when it was used in combination with FOLFIRI after progression …
colorectal cancer (mCRC) when it was used in combination with FOLFIRI after progression …
A phase I study of intravenous aflibercept with FOLFIRI in Japanese patients with previously treated metastatic colorectal cancer
T Yoshino, K Yamazaki, K Yamaguchi, T Doi… - Investigational new …, 2013 - Springer
Aflibercept, a recombinant fusion protein, is a potent inhibitor of vascular endothelial growth
factor (VEGF)-A, VEGF-B, and the placental growth factor (PlGF). The present study was an …
factor (VEGF)-A, VEGF-B, and the placental growth factor (PlGF). The present study was an …
Aflibercept versus placebo in combination with FOLFIRI in previously treated metastatic colorectal cancer (mCRC): Mean overall survival (OS) estimation from a phase …
F Joulain, E Van Cutsem, SU Iqbal, M Hoyle… - 2012 - ascopubs.org
3602 Background: VELOUR evaluated the efficacy and safety of the novel fusion protein
aflibercept (VEGF Trap) in combination with FOLFIRI in mCRC patients previously treated …
aflibercept (VEGF Trap) in combination with FOLFIRI in mCRC patients previously treated …